Jupiter Neurosciences (JUNS) announced a strategic partnership with Aquanova to jointly develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. “As we explore new ways to translate our scientific discoveries into tangible health solutions, we see an immense opportunity in the longevity and healthspan market,” said Christer Rosen, Chairman & CEO of Jupiter Neurosciences. “Aquanova has been an exceptional technology partner, and their expertise in formulation and execution will be instrumental in this venture. We believe that our pharmaceutical-driven approach and the strong clinical foundation behind JOTROL provide a unique advantage in delivering high-quality, effective products to consumers.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JUNS:
- Jupiter Neurosciences says volatility ‘appears to be driven by misconceptions’
- Jupiter Neurosciences announces JOTROL manufaturing agreement with Catalent
- Jupiter Neurosciences partners with Zina Biopharmaceuticals to advance Phase 2a
- Jupiter Neurosciences Inc trading resumes
- Jupiter Neurosciences Inc trading halted, volatility trading pause